GLS-5310 DNA初免疫苗后续接种mRNA疫苗异源加强后的免疫应答增强
在1期CoV2-001临床试验的45名参与者中,32人在完成两剂GLS-5310双顺反子DNA疫苗皮内初免后6至8个月选择接种紧急使用授权批准的SARS-CoV-2 mRNA疫苗;接种耐受良好,未报告不良事件,结合抗体滴度、中和抗体滴度和T细胞应答分别增加1,187倍、110倍和2.9倍。
要点
- GLS-5310 DNA初免后6至8个月接种mRNA疫苗耐受良好,未报告不良事件。
- 结合抗体滴度增加1,187倍,中和抗体滴度增加110倍。
- T细胞应答增加2.9倍。
核心结论
- GLS-5310 DNA初免后接种紧急使用授权批准的mRNA疫苗可增强结合抗体、中和抗体和T细胞应答,且耐受良好。
- 本文首次描述DNA初免系列后mRNA加强的异源接种免疫应答。
研究设计与样本
- 1期CoV2-001临床试验的45名参与者中,32人选择在完成两剂GLS-5310双顺反子DNA疫苗皮内初免后6至8个月接种紧急使用授权批准的SARS-CoV-2 mRNA疫苗。
- GLS-5310经皮内接种后使用GeneDerm设备施加吸引。
主要发现
- GLS-5310接种后接种紧急使用授权批准的mRNA疫苗耐受良好,未报告不良事件。
- 结合抗体滴度增加1,187倍。
- 中和抗体滴度增加110倍。
- T细胞应答增加2.9倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Heterologous boost regimens are being increasingly considered against SARS-CoV-2. We report results for the 32 of 45 participants in the Phase 1 CoV2-001 clinical trial (Kim et al., Int J Iinfect Dis 2023, 128:112-120) who elected to receive an EUA-approved SARS-CoV-2 mRNA vaccine 6 to 8 months following a two-dose primary vaccination with the GLS-5310 bi-cistronic DNA vaccine given intradermally and followed by application of suction using the GeneDerm device. Receipt of EUA-approved mRNA vaccines after GLS-5310 vaccination was well-tolerated, with no reported adverse events. Immune responses were enhanced such that binding antibody titers, neutralizing antibody titers, and T-cell responses increased 1,187-fold, 110-fold, and 2.9-fold, respectively. This paper is the first description of the immune responses following heterologous vaccination with a DNA primary series and mRNA boost.
引用
- Kim WJ, Roberts CC, Song JY, et al. Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost. Vaccine. 2023. PMID: 37296017. doi:10.1016/j.vaccine.2023.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。